Kumar Srinivasan, Ph.D., MBA

Executive Vice President, Chief Business Officer

Kumar Srinivasan, Ph.D., MBA, joined Turning Point in 2021 as executive vice president and chief business officer with responsibility for corporate strategy and business development, including collaborations and alliances.

Kumar has over 20 years of experience in pharmaceutical and biotechnology companies, most recently as vice president and global head of business development for the BioPharmaceutical business unit of AstraZeneca.

During his 9-year tenure at AstraZeneca, Dr. Srinivasan was responsible for all in- and out-licensing, business development and alliance management activities within several therapeutic areas on a regional and global scale. In addition, he previously held executive level business development roles at Wyeth; Vivoryon (formerly known as Probiodrug), a publicly traded biotech based in Germany; and Torrey Pines Therapeutics. Earlier in his career, he held scientific roles at biopharmaceutical companies, Sibia Neurosciences and Genta.

He has a Ph.D from Case Western University in chemistry, did his postdoctoral work at Caltech under Professor Frances Arnold and has an MBA with a concentration in finance and strategy from the University of Chicago’s Booth School of Business.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb